Indication:

Spanbec^® is indicated as an adjunct to diet and exercise to lower blood glucose in patients with noninsulin-dependent (type 2) Diabetes Mellitus (NIDDM).

Dosage & Administration:

1 mg once daily. If necessary, the daily dose can be increased. Any increase can be based on regular blood sugar monitoring, and should be gradual. The maximum starting dose of Spanbec^® should be no more than 2 mg. Usual maintenance dose: The usual maintenance dose is 1 to 4 mg once daily. The maximum recommended dose is 8 mg once daily. Administer once daily with meal preferably in the evening. Gradually escalate the dose to reduce the gastrointestinal side effects due to Metformin. May adjust the dosing based on effectiveness & tolerability while not exceeding the maximum daily dose of 100 mg Sitagliptin& and 2000 mg Metformin. Maintain the same total daily dose when changing between Sitaglip-M^®50/500 &Sitaglip-M^® 50/1000 without exceeding the maximum recommended daily dose of 2000 mg Metformin. Patients using two Sitaglip-M^® tablets (such as two Sitaglip-M^® 50/500 or two Sitaglip-M 50/1000 tablets) should take the two tablets together once daily. 100 mg Sitagliptin/2000 mg Metformin HCl XR tablets should be taken once daily.

Preparation:

Spanbec^®1 Tablet: Each box contains 30 x 5 tablets in blister pack.
Spanbec^®2 Tablet: Each box contains 30 x 5 tablets in blister pack.
Spanbec^®3 Tablet: Each box contains 30 x 5 tablets in blister pack.
Spanbec^®4 Tablet: Each box contains 20 x 5 tablets in blister pack.